• Publications
  • Influence
Postmenopausal hormone therapy: an Endocrine Society scientific statement.
TLDR
A scholarly review of the published literature on menopausal hormonal therapy (MHT), make scientifically valid assessments of the available data, and grade the level of evidence available for each clinically important endpoint to arrive at major conclusions. Expand
Progesterone Receptor Modulator for Emergency Contraception: A Randomized Controlled Trial
TLDR
CDB-2914 is at least as effective as levonorgestrel in preventing pregnancies after unprotected intercourse and has a similar side effect profile. Expand
Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel.
TLDR
Use of Implanon for up to 2 years had no clinically significant effects on laboratory parameters, physical and pelvic examinations, vital signs or body mass index. Expand
Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
TLDR
BZA/CE showed low rates of endometrial hyperplasia and improved lumbar spine and total hip BMD and was generally safe and well tolerated. Expand
The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy.
TLDR
It appears that women do not respond to exogenous progestins with the dramatic vaginal thinning seen in rhesus monkeys, and there was no significant change over time in vaginal epithelial thickness and number of cell layers from biopsies taken in the untreated follicular and luteal phases. Expand
Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment.
TLDR
A brief summary of the pharmacology of EE and E₂, including metabolism, pharmacokinetics and pharmacodynamics, as well as adverse effects of these estrogens are provided. Expand
Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women.
TLDR
Postmenopausal women treated with BZA 20 or 40 mg with CE 0.625 or 0.45 mg had high rates of cumulative amenorrhea that were similar to those reported with placebo, and this new menopausal therapy may offer a favorable bleeding and tolerability profile. Expand
Menopausal hot flushes and night sweats: where are we now?
TLDR
Hot flushes are caused by changes in the central nervous system associated with estrogen withdrawal and are best treated with estrogen replacement therapy, and Objective monitoring of hot flushes indicates that placebo has little to no effect on their improvement. Expand
Efficacy and tolerability of local estrogen therapy for urogenital atrophy
TLDR
Urogenital atrophy should not be considered an inevitable consequence of menopause because various hormonal and nonhormonal products are available to relieve symptoms, and postmenopausal estrogen therapy is the most logical choice for treatment. Expand
Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial
TLDR
The use of drospirenone combined with estradiol provides protection against endometrial hyperplasia, reduces endometrian bleeding with time, and relieves menopausal symptoms. Expand
...
1
2
3
4
5
...